TSA gene of Leishmania major cloned in eukaryotic expression vector could stimulated immune system in mice
Abstract number: P1330
Ghaffarifar F., Tabatabaie F., Sharifi Z., Dalimi Asl A., Ghasemi S., Ghafarifar M.
Objectives: TSA (thiol-specific-antioxidant antigen) is the immuno-dominant antigen of Leishmania major considered as the most promising molecule for a recombinant or DNA vaccine candidate against leishmaniasis. In the present work.
Methods: Genomic DNA of TSA protein was extracted and amplificated as a template. The PCR product has cloned into pTZ57R/T vector followed by subcloning into the eukaryotic expression vector pcDNA3 (EcoRI and HindIII sites). The expression of plasmid containing TSA gene was demonstrated by SDS-PAGE and Western-blot. These results indicated successful expression of plasmid containing TSA gene in eukaryotic cells.
Results: In the present study, we evaluated TSA-encoded DNA vaccine against L. major in BALB/C mice. IgG and IFN-g values were markedly increased in the immunised group, which were significantly higher than in the control groups (p < 0.05) following immunisation and after challenge with Leishmania major. IL-4 values were increased in all groups, but there was no statistical difference between the groups (p > 0.05) following immunisation and after challenge with Leishmania major.
Conclusion: The findings of this study indicated that the TSA-encoded DNA vaccine increased the cellular response and induced protection against infection with Leishmania in the mice. The TSA-encoded DNA vaccine may be an excellent candidate for future vaccine developments against Leishmania.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|